Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Down 24.9% in March

Key Points

• Short interest down 24.9% — as of March 31 short interest fell to 1,494,814 shares (about 9.5% of shares sold short), producing a short‑interest ratio of 2.6 days based on average volume.
• Keros missed quarterly expectations, reporting EPS of -$0.86 vs. -$0.49 expected and revenue of $0.39M vs. $3.66M expected, with revenue down 87.2% year‑over‑year; analysts project -4.74 EPS for the current year.
• The stock trades near $11.71 with a market cap of roughly $231M, a consensus "Hold" rating and $21.33 target, and about 71.6% of shares are held by institutional investors who have recently increased positions.

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) was the target of a significant decline in short interest in March. As of March 31st, there was short interest totaling 1,494,814 shares, a decline of 24.9% from the March 15th total of 1,989,399 shares. Currently, 9.5% of the shares of the company are sold short. Based on an average trading volume of 568,956 shares, the short-interest ratio is presently 2.6 days.

Keros Therapeutics Trading Up 1.4%

Shares of NASDAQ KROS traded up $0.16 during midday trading on Wednesday, reaching $11.71. 305,226 shares of the stock were exchanged, compared to its average volume of 416,665. The company has a market capitalization of $230.92 million, a P/E ratio of 6.43 and a beta of 0.98. Keros Therapeutics has a 52-week low of $10.41 and a 52-week high of $22.55. The stock has a 50 day moving average price of $13.34 and a 200-day moving average price of $16.28.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings results on Wednesday, March 4th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.37). The firm had revenue of $0.39 million for the quarter, compared to analysts' expectations of $3.66 million. Keros Therapeutics had a return on equity of 14.25% and a net margin of 35.65%.The business's quarterly revenue was down 87.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.14) earnings per share. On average, analysts forecast that Keros Therapeutics will post -4.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on KROS. Wall Street Zen cut shares of Keros Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, March 7th. Weiss Ratings restated a "sell (d+)" rating on shares of Keros Therapeutics in a research report on Monday, December 29th. Zacks Research cut shares of Keros Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Thursday, January 1st. TD Cowen upgraded shares of Keros Therapeutics to a "hold" rating in a research report on Friday, December 19th. Finally, Wells Fargo & Company cut their target price on shares of Keros Therapeutics from $23.00 to $20.00 and set an "overweight" rating for the company in a research report on Thursday, March 5th. Four analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $21.33.

Institutional Investors Weigh In On Keros Therapeutics

Institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC grew its holdings in Keros Therapeutics by 1,420.6% in the fourth quarter. SG Americas Securities LLC now owns 98,703 shares of the company's stock valued at $2,010,000 after purchasing an additional 92,212 shares during the period. Assenagon Asset Management S.A. grew its stake in Keros Therapeutics by 154.2% during the third quarter. Assenagon Asset Management S.A. now owns 257,518 shares of the company's stock worth $4,074,000 after buying an additional 156,221 shares during the period. Western Standard LLC grew its stake in Keros Therapeutics by 42.7% during the third quarter. Western Standard LLC now owns 2,189,882 shares of the company's stock worth $34,644,000 after buying an additional 654,989 shares during the period. JPMorgan Chase & Co. grew its stake in Keros Therapeutics by 260.8% during the third quarter. JPMorgan Chase & Co. now owns 171,941 shares of the company's stock worth $2,720,000 after buying an additional 124,287 shares during the period. Finally, Cornerstone Investment Partners LLC purchased a new stake in Keros Therapeutics during the third quarter worth approximately $176,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc NASDAQ: KROS is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company's research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company's lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.